drugset / Trial / NCT07672717
Cabotegravir-Hormone PK/PD Interactions for HIV Prevention
Phase 1
Recruiting
32 enrolled
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID) · collab
NaSingle-groupOpen-labelPrevention
Summary
This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical problems when taking CAB-LA.
Timeline
- Start
- 2026-07-07
- Primary completion
- 2030-12
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabotegravir | Small molecule | 600 mg | — |